PJP:NYE-Invesco Dynamic Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 86.5223

Change

-0.45 (-0.51)%

Market Cap

N/A

Volume

4.96K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

-0.31 (-0.20%)

USD 41.71B
FHLC Fidelity® MSCI Health Care In..

-0.08 (-0.11%)

USD 2.97B
FXH First Trust Health Care AlphaD..

-0.78 (-0.71%)

USD 1.29B
XHE SPDR® S&P Health Care Equipme..

-0.33 (-0.37%)

USD 0.22B
IDNA iShares Genomics Immunology an..

+0.03 (+0.12%)

USD 0.14B
SBIO ALPS Medical Breakthroughs ETF

+0.02 (+0.06%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

-0.11 (-0.12%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.02 (-0.06%)

USD 0.06B
BBP Virtus LifeSci Biotech Product..

+0.70 (+1.13%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.05 (+0.18%)

USD 0.01B

ETFs Containing PJP

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.70% 90% A- 67% D+
Dividend Return 0.76% 56% F 12% F
Total Return 14.46% 95% A 61% D-
Trailing 12 Months  
Capital Gain 22.17% 67% D+ 57% F
Dividend Return 1.09% 56% F 12% F
Total Return 23.26% 71% C- 50% F
Trailing 5 Years  
Capital Gain 53.68% 62% D 71% C-
Dividend Return 4.24% 56% F 12% F
Total Return 57.92% 57% F 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 6.57% N/A N/A 60% D-
Dividend Return 7.16% N/A N/A 54% F
Total Return 0.59% N/A N/A 14% F
Risk Return Profile  
Volatility (Standard Deviation) 12.91% N/A N/A 70% C-
Risk Adjusted Return 55.51% N/A N/A 72% C
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike